Eli Lilly (LLY) Net Margin Growth (3y) (2012 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Margin Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
1,803.00 |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
1,973.00 |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
544.00 |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-4,534.00 |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-2,543.00 |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
1,355.00 |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-58.00 |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
332.00 |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
1,803.00 |
| Dec 31, 2025 |
787.00 |
| Sep 30, 2025 |
1,080.00 |
| Jun 30, 2025 |
2,170.00 |
| Mar 31, 2025 |
-269.00 |
| Dec 31, 2024 |
1,101.00 |
| Sep 30, 2024 |
-791.00 |
| Jun 30, 2024 |
562.00 |
| Mar 31, 2024 |
567.00 |
| Mar 31, 2022 |
-4,791.00 |
| Dec 31, 2021 |
2,151.00 |
| Sep 30, 2021 |
1,534.00 |
| Jun 30, 2021 |
2,113.00 |
| Mar 31, 2021 |
1,890.00 |
| Mar 31, 2019 |
6,323.00 |
| Dec 31, 2018 |
-848.00 |
| Sep 30, 2018 |
-1,507.00 |
| Jun 30, 2018 |
-1,257.00 |
| Mar 31, 2018 |
-1,039.00 |
| Dec 31, 2017 |
-3,323.00 |
| Sep 30, 2017 |
-45.00 |
| Jun 30, 2017 |
245.00 |
| Mar 31, 2017 |
-1,766.00 |
| Dec 31, 2016 |
103.00 |
| Sep 30, 2016 |
-586.00 |
| Jun 30, 2016 |
-651.00 |
| Mar 31, 2016 |
-1,859.00 |
| Dec 31, 2015 |
-519.00 |
| Sep 30, 2015 |
-825.00 |
| Jun 30, 2015 |
-442.00 |
| Mar 31, 2015 |
-665.00 |
| Dec 31, 2014 |
-622.00 |
| Sep 30, 2014 |
-984.00 |
| Jun 30, 2014 |
-429.00 |
| Mar 31, 2014 |
-254.00 |
| Dec 31, 2013 |
-654.00 |
| Sep 30, 2013 |
-290.00 |
| Jun 30, 2013 |
-379.00 |
| Mar 31, 2013 |
488.00 |
| Dec 31, 2012 |
-169.00 |
| Sep 30, 2012 |
689.00 |
| Jun 30, 2012 |
-540.00 |
| Mar 31, 2012 |
-797.00 |
